Clinical Trial: Neurotropism and Neuroinflammation in COVID-19 Patients With Delirium

U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT04785157) titled 'Neurotropism and Neuroinflammation in COVID-19 Patients With Delirium' on March 2.

Brief Summary: Emerging evidence indicates that SARS-CoV-2, the etiologic agent of COVID-19, can cause neurological, neuropsychological and psychiatric complications. Given the global dimensions of the current pandemic, there is to consider the possible large-scale neurocognitive impact of COVID-19. Therefore, there is an urgent need for longitudinal studies to determine the acute and chronic effects that COVID-19 may have on the Central Nervous System. These putative effects include the possibility that the CNS serves as a reservoir for the virus, an...